ANTX
NASDAQAN2 Therapeutics Inc.
Price$4.21-1.02 (-19.50%)
2026-03-092026-06-10
News · 26 weeks70-64%
2025-12-142026-06-07
Mix4190d
- Insider16(39%)
- SEC Filings15(37%)
- Other9(22%)
- Analyst1(2%)
Latest news
25 items- SECAN2 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas DiseaseParasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of ch
- INSIDERPrincipal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- PRAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare ConferenceAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AN2 Therapeutics Inc.SCHEDULE 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
- ANALYSTAN2 Therapeutics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $9.00
- SECSEC Form 10-Q filed by AN2 Therapeutics Inc.10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECAN2 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific HighlightsOral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study Declared ENPP1 candidate for solid tumors advancing from early research into development AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first
- PRAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical
- SECSEC Form DEF 14A filed by AN2 Therapeutics Inc.DEF 14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form DEFA14A filed by AN2 Therapeutics Inc.DEFA14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form EFFECT filed by AN2 Therapeutics Inc.EFFECT - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 424B3 filed by AN2 Therapeutics Inc.424B3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 424B5 filed by AN2 Therapeutics Inc.424B5 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- INSIDERSEC Form 4 filed by Aziz Kabeer4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Martin Patricia A.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SECSEC Form S-3 filed by AN2 Therapeutics Inc.S-3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECSEC Form 8-K filed by AN2 Therapeutics Inc.8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung DiseaseAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessus (M. abscessus). The 84-patient, multicenter, randomized, double-blind study is being led by Dr. Kevin Winthrop at Oregon Health & Science University (OHSU), in collaboration with other investigators across an estimated 10-15 sites in th
- SECSEC Form D filed by AN2 Therapeutics Inc.D - AN2 Therapeutics, Inc. (0001880438) (Filer)
- INSIDERSEC Form 4 filed by Day Lucy4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Chanda Sanjay4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by Marks Gilbert Lynn4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
ANTX FAQ
7 questionsWhat does AN2 Therapeutics Inc. do?
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.Where does ANTX stock trade?
AN2 Therapeutics Inc. (ANTX) is listed on NASDAQ.What sector and industry is ANTX in?
AN2 Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AN2 Therapeutics Inc. go public?
AN2 Therapeutics Inc. (ANTX) completed its IPO in 2022.What are analysts saying about ANTX?
AN2 Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $900.00 price target on 2026-05-14.What companies are similar to ANTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANTX side-by-side with any of them on Quantisnow.How can I track ANTX on Quantisnow?
Quantisnow aggregates AN2 Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANTX to receive live email and push alerts on every new disclosure.